Amyotrophic Lateral Sclerosis (ALS) Genetic Variants

Amyotrophic Lateral Sclerosis (ALS) Genetic Variants

Introduction

Amyotrophic Lateral Sclerosis (Als) Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor [neurons](/entities/neurons). Approximately 5-10% of ALS cases are familial, with over 30 genes implicated in disease pathogenesis. This page summarizes the key genetic variants associated with ALS, their molecular mechanisms, clinical implications, and therapeutic relevance. [@superoxide]

Overview

Amyotrophic lateral sclerosis affects approximately 30,000 Americans, with an incidence of 1-2 per 100,000 people annually. The disease typically presents in mid-life (55-65 years) with progressive muscle weakness, atrophy, and eventual respiratory failure. Genetic factors play a significant role in both familial and sporadic forms of ALS. [@early]

The genetic architecture of ALS includes: [@tofersen]

• Major causal genes: C9orf72, SOD1, FUS, TARDBP (accounting for ~70% of familial ALS)
• Moderate risk genes: UBQLN2, OPTN, TBK1, VCP, ANG
• GWAS-identified loci: Over 15 risk loci identified through genome-wide studies

Major Causal Genes

C9orf72

Amyotrophic Lateral Sclerosis (ALS) Genetic Variants

Introduction

Amyotrophic Lateral Sclerosis (Als) Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor [neurons](/entities/neurons). Approximately 5-10% of ALS cases are familial, with over 30 genes implicated in disease pathogenesis. This page summarizes the key genetic variants associated with ALS, their molecular mechanisms, clinical implications, and therapeutic relevance. [@superoxide]

Overview

Amyotrophic lateral sclerosis affects approximately 30,000 Americans, with an incidence of 1-2 per 100,000 people annually. The disease typically presents in mid-life (55-65 years) with progressive muscle weakness, atrophy, and eventual respiratory failure. Genetic factors play a significant role in both familial and sporadic forms of ALS. [@early]

The genetic architecture of ALS includes: [@tofersen]

• Major causal genes: C9orf72, SOD1, FUS, TARDBP (accounting for ~70% of familial ALS)
• Moderate risk genes: UBQLN2, OPTN, TBK1, VCP, ANG
• GWAS-identified loci: Over 15 risk loci identified through genome-wide studies

Major Causal Genes

C9orf72

The C9orf72 gene on chromosome 9p21 encodes a DENN domain protein involved in endosomal trafficking and [autophagy](/entities/autophagy). A hexanucleotide repeat expansion (GGGGCC) in the first intron represents the most common genetic cause of ALS, accounting for approximately 40% of familial ALS and 5-10% of sporadic ALS cases. [@advancement]

The pathogenic potential of C9orf72 expansions is determined by repeat length, with normal individuals carrying fewer than 30 repeats, intermediate carriers having 30-60 repeats, and pathogenic expansions exceeding 60 repeats that can extend to hundreds or thousands of copies. The penetrance of these expansions is age-dependent, with 50% of carriers becoming symptomatic by age 58. Clinically, affected individuals typically present with classic ALS or fall within the ALS/FTD spectrum, reflecting the diverse mechanisms underlying C9orf72 pathology.

The expansion leads to a complex cascade of cellular dysfunction through three primary mechanisms. First, toxic RNA foci form when the expanded transcripts sequester essential RNA-binding proteins, disrupting normal RNA processing. In addition to this RNA toxicity, the repeat-containing transcripts undergo repeat-associated non-ATG translation to produce dipeptide repeat proteins (DPRs), including poly-GA, poly-GP, and poly-GR species that severely impair cellular proteostasis. This is further complicated by haploinsufficiency, as reduced C9orf72 protein levels affect normal lysosomal trafficking and autophagy pathways.

[C9orf72 Gene](/entities/c9orf72) - Full gene page

SOD1 (Superoxide Dismutase 1)

The SOD1 gene on chromosome 21 encodes copper/zinc superoxide dismutase, a key antioxidant enzyme critical for cellular protection against oxidative damage. Over 180 pathogenic mutations in this gene cause approximately 15-20% of familial ALS cases, primarily through toxic gain-of-function mechanisms rather than simple loss of enzymatic activity.

Several SOD1 mutations demonstrate distinct geographic and clinical patterns. The A4V mutation represents the most common variant in North America and is associated with rapid disease progression. Similarly aggressive is the G93A mutation, which has become widely used in research models due to its consistent phenotype. In contrast, the H46R mutation predominates in Japanese populations and typically follows a slower progression course. The D90A mutation, found primarily in Scandinavian populations, exhibits variable phenotypic expression that can range from typical to more indolent disease courses.

The mechanisms underlying SOD1 toxicity involve multiple interconnected pathways that collectively drive motor neuron degeneration. Mutant SOD1 proteins undergo misfolding and subsequent aggregation, forming toxic inclusions that disrupt cellular homeostasis. This is accompanied by significant mitochondrial dysfunction that impairs energy production and calcium handling. Concurrently, affected cells experience heightened oxidative stress despite the protein's normal antioxidant function. The pathogenic process is further exacerbated by impaired axonal transport, which compromises the delivery of essential materials along motor neuron processes. Additionally, glial cell dysfunction, particularly in astrocytes and microglia, contributes to the inflammatory environment that accelerates neurodegeneration.

[SOD1 Gene](/entities/sod1) - Full gene page

FUS (Fused in Sarcoma)

The FUS gene on chromosome 16 encodes an RNA-binding protein with critical roles in transcription regulation, RNA splicing, and RNA transport throughout the cell. Mutations in FUS cause approximately 5% of familial ALS cases and are typically characterized by early onset, with symptoms commonly appearing between 30-40 years of age.

The primary pathogenic mechanism involves a nuclear import defect, where mutations impair FUS nuclear localization, leading to cytoplasmic accumulation and subsequent formation of stress granules and pathological inclusions.

Moderate Risk Genes

UBQLN2

The UBQLN2 gene on chromosome X encodes ubiquilin-2, a protein involved in protein degradation through the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system). X-linked dominant mutations cause ALS with dementia.

OPTN (Optineurin)

The OPTN gene encodes optineurin, involved in autophagy and [NF-κB](/entities/nf-kb) signaling. Mutations cause both ALS and glaucoma.

TBK1

The TBK1 gene encodes TANK-binding kinase 1, a key regulator of autophagy and innate immunity. Loss-of-function mutations cause ALS/FTD.

VCP (Valosin-Containing Protein)

The VCP gene mutations cause inclusion body myopathy with early-onset Paget disease and ALS (IBMPFD).

ANG (Angiogenin)

The ANG gene encodes angiogenin, a secreted ribonuclease with roles in stress response and angiogenesis.

GWAS-Identified Risk Loci

Genome-wide association studies have identified multiple ALS risk loci:

| Gene/Region | Chromosome | Odds Ratio | Function |
|-------------|------------|------------|----------|
| UNC13A | 19p13 | 1.2 | Synaptic vesicle release |
| SOD1 | 21q22 | 1.3 | Antioxidant enzyme |
| ATXN2 | 12q24 | 1.3 | RNA processing |
| DCTN1 | 2p13 | 1.2 | Axonal transport |
| CHCHD10 | 22q11 | 1.5 | Mitochondrial function |

Therapeutic Implications

Genetic testing is increasingly important for:

• Diagnosis confirmation: Establishing definitive etiology
• Prognosis: Certain mutations predict faster progression
• Family screening: Identifying at-risk relatives
• Clinical trials: Genetic stratification for targeted therapies

Gene-Specific Therapies in Development

Background

The study of Amyotrophic Lateral Sclerosis (Als) Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease, spanning advances in disease mechanisms, therapeutic interventions, and clinical phenotypes observed between 2024 and 2026.

Recent mechanistic insights have emerged regarding the prion-like propagation characteristics of ALS pathology. Research published in December 2026 demonstrated efficient induction of motor neuron disease in transgenic G93A SOD1 mice through prion-like seeding mechanisms, providing crucial evidence for the transmissible nature of protein misfolding in ALS progression. This is further supported by findings published in April 2026 in Free Radical Biology & Medicine, which revealed that superoxide dismutase significantly impacts both extracellular vesicle shedding and uptake processes, suggesting a novel pathway through which SOD1 dysfunction may contribute to intercellular spread of pathological changes.

In addition to mechanistic discoveries, important clinical phenotype correlations have been identified across different genetic variants. Research published in April 2026 in Muscle & Nerve established that early dropped head syndrome demonstrates higher prevalence specifically in patients carrying C9orf72 and FUS/TLS mutations, indicating that certain genetic backgrounds may predispose to distinct clinical presentations and potentially informing diagnostic approaches.

Therapeutic advancement has also progressed significantly, particularly for SOD1-related ALS cases. A real-world outcomes study published in March 2026 in Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration examined tofersen treatment effectiveness in a genetically homogeneous Croatian cohort carrying the SOD1 p.Leu145Phe variant, providing valuable evidence for precision medicine approaches in ALS management. This clinical progress is complemented by emerging technological innovations, as highlighted by research published in Drug Delivery and Translational Research in March 2026, which explored the advancement of quantum dots as therapeutic delivery systems in amyotrophic lateral sclerosis, outlining both current opportunities and existing challenges in this novel therapeutic approach.

References

• ALS- C9orf7- SOD1 Gene
• FUS Gene
• [ALS Treatment Approaches](/therapeutics)

External Lin

• [ALS Assoc- [ALS Therapy Development Institute](https://www.als.net)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=ALS+genetics+amyotrophic+lateral+sclerosis)